Windtree Therapeutics Amends S-1 for Continuous Offering

TL;DR

**WINTW is setting up for a potential capital raise, brace for possible dilution.**

AI Summary

WINDTREE THERAPEUTICS INC /DE/ filed an S-1/A on July 10, 2025, as Amendment No. 2 to its S-1 Registration Statement (Registration No. 333-287358) under the Securities Act of 1933. The filing indicates a proposed sale of securities on a delayed or continuous basis pursuant to Rule 415, suggesting a potential capital raise or offering. The company, classified under SIC 2836 (Biological Products), maintains its principal executive offices at 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976, with a business phone of (215) 488-9300. Jed Latkin serves as President and Chief Executive Officer, and is also the agent for service. The filing does not provide specific revenue or net income figures, nor does it detail key business changes or strategic outlook beyond the intent to offer securities. Risks are implicitly tied to the nature of a continuous offering and the inherent uncertainties of a biotechnology company. The document primarily updates registration details for the offering.

Why It Matters

This S-1/A filing signals Windtree Therapeutics' intent to potentially raise capital through a continuous offering, which could dilute existing shareholders if new shares are issued. For investors, understanding the terms of this offering, once fully disclosed, will be crucial for valuation. Employees might see this as a move to secure long-term funding for ongoing research and development in the competitive biological products sector. Customers could benefit from continued product development, while the broader market will watch how Windtree leverages this potential capital in a highly competitive biotech landscape, especially against larger players with more robust funding.

Risk Assessment

Risk Level: medium — The filing indicates a proposed sale of securities on a delayed or continuous basis pursuant to Rule 415, which inherently carries dilution risk for existing shareholders if new equity is issued. As a biotechnology company (SIC 2836), Windtree Therapeutics faces significant R&D and regulatory approval risks, which are common in the sector and can impact the success of any capital raised.

Analyst Insight

Investors should monitor subsequent filings for specific details on the offering, including the type and amount of securities to be sold, to assess potential dilution and the company's funding strategy. Evaluate Windtree's current cash position and burn rate to understand the urgency and necessity of this continuous offering.

Key Numbers

• 333-287358 — Registration Number (Identifies the specific S-1 registration statement being amended.)
• 2836 — SIC Code (Classifies Windtree Therapeutics as a Biological Products company, indicating its industry.)
• 2025-07-10 — Filing Date (The date the S-1/A amendment was filed with the SEC.)
• 2 — Amendment Number (This is the second amendment to the original S-1 registration statement.)
• 94-3171943 — IRS Employer Identification No. (Unique tax identification number for Windtree Therapeutics.)

Key Players & Entities

• WINDTREE THERAPEUTICS INC /DE/ (company) — Registrant and filer of S-1/A
• Jed Latkin (person) — President and Chief Executive Officer, Agent for Service
• Faith L. Charles, Esq. (person) — Legal counsel from Thompson Hine LLP
• Thompson Hine LLP (company) — Legal firm providing counsel
• Securities and Exchange Commission (regulator) — Regulatory body for the S-1/A filing
• 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976 (company) — Principal executive offices address
• 215-488-9300 (dollar_amount) — Business phone number
• 0000946486 (company) — Central Index Key (CIK) for Windtree Therapeutics
• 333-287358 (regulator) — Registration No. for the S-1 filing
• Rule 415 (regulator) — SEC rule governing delayed or continuous offerings

FAQ

Industry Context

Windtree Therapeutics operates in the biotechnology sector, specifically focusing on biological products. This industry is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this space often rely on continuous capital raises to fund their operations and clinical trials.

Regulatory Implications

As a biotechnology company pursuing a securities offering, Windtree Therapeutics is subject to stringent SEC regulations. The S-1/A filing indicates ongoing compliance efforts. Furthermore, the development and commercialization of biological products are heavily regulated by agencies like the FDA, posing inherent risks and requiring substantial investment in compliance.

What Investors Should Do

1. Monitor SEC filings for further amendments to the S-1/A.
2. Research the company's pipeline and clinical trial progress.
3. Assess the company's cash burn rate and runway.

Key Dates

• 2025-07-10: Filing of Amendment No. 2 to S-1 Registration Statement — Indicates the company is actively pursuing a delayed or continuous offering of securities, suggesting a need for capital.

Glossary

S-1/A

An amendment to an S-1 Registration Statement filed with the SEC. It's used to update or correct information in the original filing. (This filing is an amendment to the company's initial registration statement, showing ongoing activity related to a securities offering.)

Rule 415

A SEC rule that permits companies to register securities for a 'delayed or continuous offering' on a 'shelf' basis. (The company is utilizing Rule 415, indicating they plan to sell securities over time as market conditions or capital needs dictate.)

SIC Code 2836

Standard Industrial Classification code for Biological Products (No Diagnostic Substances). (Classifies Windtree Therapeutics within the biotechnology sector, specifically focusing on biological products.)

Registration Statement

A document required by the SEC for public offerings of securities, containing detailed information about the company and the offering. (The S-1/A is an update to the initial registration statement, which is a prerequisite for raising capital through public markets.)

Year-Over-Year Comparison

This filing is Amendment No. 2 to the S-1 Registration Statement. As it is an amendment to an initial registration statement and does not appear to contain comparative financial data from a prior period within this specific amendment document, a direct comparison of key metrics like revenue growth or margin changes to a previous year is not possible based solely on this filing. The primary focus of this amendment is to update registration details for a delayed or continuous offering.

Filing Details

This Form S-1/A (Form S-1/A) was filed with the SEC on July 10, 2025 by Jed Latkin regarding WINDTREE THERAPEUTICS INC /DE/ (WINTW).

View full filing on EDGAR

View Full Filing

View this S-1/A filing on SEC EDGAR